Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)

"* The initial cohort dose of infigratinib will begin at the protocol-specified starting dose, with subsequent cohort escalation based on protocol specific criteria.~* The target dose is the dose that will provide similar exposure to the dose of 0.25 mg/kg/day in participants 3 years old and older.~* The dose and number of minitablets will be calculated based on individual participant age and weight."

"* The cohort dose of infigratinib will be the dose identified in the Single Ascending Dose portion for the age group.~* The dose and number of sprinkle capsules/day will be calculated based on individual participant age and weight. Doses will be adjusted based on age and weight changes approximately every 3 months."

"* The cohort dose of infigratinib or placebo will be the dose confirmed in the Phase 2 portion for the age group.~* The dose and number of sprinkle capsules/day will be calculated based on individual participant age and weight. Doses will be adjusted based on age and weight changes approximately every 3 months."

"* The dose of infigratinib will be the dose confirmed in the Phase 2 portion and used in the Phase 2b portion for the age group.~* The dose and number of sprinkle capsules/day will be calculated based on individual participant age and weight. Doses will be adjusted based on age and weight changes approximately every 3 months for the first year and every 6 months thereafter."